vs
碧迪（BDX）与Entergy（ETR）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是Entergy的1.8倍（$5.3B vs $3.0B），Entergy净利率更高（8.1% vs 7.3%，领先0.9%），Entergy同比增速更快（7.9% vs -0.4%），碧迪自由现金流更多（$549.0M vs $-909.7M），过去两年Entergy的营收复合增速更高（2.9% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
Entergy是美国能源企业，主营电力生产及零售配送业务，服务覆盖美国南部腹地，总部设于路易斯安那州新奥尔良。公司为阿肯色、路易斯安那、密西西比、得克萨斯四州共300万用户供电，发电装机容量约24000兆瓦，年营收110亿美元，员工规模超12000人。
BDX vs ETR — 直观对比
营收规模更大
BDX
是对方的1.8倍
$3.0B
营收增速更快
ETR
高出8.3%
-0.4%
净利率更高
ETR
高出0.9%
7.3%
自由现金流更多
BDX
多$1.5B
$-909.7M
两年增速更快
ETR
近两年复合增速
2.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $3.0B |
| 净利润 | $382.0M | $240.5M |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | 18.4% |
| 净利率 | 7.3% | 8.1% |
| 营收同比 | -0.4% | 7.9% |
| 净利润同比 | 24.0% | -16.2% |
| 每股收益（稀释后） | $1.34 | $0.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXETR
| Q4 25 | $5.3B | $3.0B | ||
| Q3 25 | $5.9B | $3.8B | ||
| Q2 25 | $5.5B | $3.3B | ||
| Q1 25 | $5.3B | $2.8B | ||
| Q4 24 | $5.2B | $2.7B | ||
| Q3 24 | $5.4B | $3.4B | ||
| Q2 24 | $5.0B | $3.0B | ||
| Q1 24 | $5.0B | $2.8B |
净利润BDXETR
| Q4 25 | $382.0M | $240.5M | ||
| Q3 25 | $493.0M | $698.4M | ||
| Q2 25 | $574.0M | $472.0M | ||
| Q1 25 | $308.0M | $362.4M | ||
| Q4 24 | $303.0M | $287.2M | ||
| Q3 24 | $400.0M | $645.8M | ||
| Q2 24 | $487.0M | $51.7M | ||
| Q1 24 | $537.0M | $76.5M |
毛利率BDXETR
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.7% | — |
营业利润率BDXETR
| Q4 25 | 10.5% | 18.4% | ||
| Q3 25 | 11.8% | 29.4% | ||
| Q2 25 | 16.0% | 25.2% | ||
| Q1 25 | 10.4% | 24.6% | ||
| Q4 24 | 8.8% | 24.4% | ||
| Q3 24 | 11.4% | 33.2% | ||
| Q2 24 | 12.1% | 20.9% | ||
| Q1 24 | 14.5% | 8.5% |
净利率BDXETR
| Q4 25 | 7.3% | 8.1% | ||
| Q3 25 | 8.4% | 18.3% | ||
| Q2 25 | 10.4% | 14.2% | ||
| Q1 25 | 5.8% | 12.7% | ||
| Q4 24 | 5.9% | 10.5% | ||
| Q3 24 | 7.4% | 19.1% | ||
| Q2 24 | 9.8% | 1.8% | ||
| Q1 24 | 10.6% | 2.7% |
每股收益（稀释后）BDXETR
| Q4 25 | $1.34 | $0.51 | ||
| Q3 25 | $1.71 | $1.53 | ||
| Q2 25 | $2.00 | $1.05 | ||
| Q1 25 | $1.07 | $0.82 | ||
| Q4 24 | $1.04 | $0.66 | ||
| Q3 24 | $1.37 | $1.50 | ||
| Q2 24 | $1.68 | $0.11 | ||
| Q1 24 | $1.85 | $0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $1.9B |
| 总债务越低越好 | — | $30.3B |
| 股东权益账面价值 | $25.3B | $16.9B |
| 总资产 | $54.8B | $71.9B |
| 负债/权益比越低杠杆越低 | — | 1.79× |
8季度趋势，按日历期对齐
现金及短期投资BDXETR
| Q4 25 | $740.0M | $1.9B | ||
| Q3 25 | $641.0M | $1.5B | ||
| Q2 25 | $735.0M | $1.2B | ||
| Q1 25 | $667.0M | $1.5B | ||
| Q4 24 | $711.0M | $859.7M | ||
| Q3 24 | $1.7B | $1.4B | ||
| Q2 24 | $4.5B | $1.4B | ||
| Q1 24 | $2.3B | $1.3B |
总债务BDXETR
| Q4 25 | — | $30.3B | ||
| Q3 25 | — | $29.0B | ||
| Q2 25 | — | $29.9B | ||
| Q1 25 | — | $29.6B | ||
| Q4 24 | — | $28.0B | ||
| Q3 24 | — | $27.9B | ||
| Q2 24 | — | $27.8B | ||
| Q1 24 | — | $26.5B |
股东权益BDXETR
| Q4 25 | $25.3B | $16.9B | ||
| Q3 25 | $25.4B | $16.7B | ||
| Q2 25 | $25.5B | $16.2B | ||
| Q1 25 | $25.2B | $15.2B | ||
| Q4 24 | $25.2B | $15.1B | ||
| Q3 24 | $25.9B | $15.0B | ||
| Q2 24 | $25.9B | $14.6B | ||
| Q1 24 | $25.6B | $14.5B |
总资产BDXETR
| Q4 25 | $54.8B | $71.9B | ||
| Q3 25 | $55.3B | $69.8B | ||
| Q2 25 | $54.9B | $68.4B | ||
| Q1 25 | $54.5B | $66.6B | ||
| Q4 24 | $54.7B | $64.8B | ||
| Q3 24 | $57.3B | $64.5B | ||
| Q2 24 | $55.6B | $62.8B | ||
| Q1 24 | $54.2B | $61.6B |
负债/权益比BDXETR
| Q4 25 | — | 1.79× | ||
| Q3 25 | — | 1.74× | ||
| Q2 25 | — | 1.85× | ||
| Q1 25 | — | 1.95× | ||
| Q4 24 | — | 1.86× | ||
| Q3 24 | — | 1.85× | ||
| Q2 24 | — | 1.91× | ||
| Q1 24 | — | 1.83× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $1.2B |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $-909.7M |
| 自由现金流率自由现金流/营收 | 10.5% | -30.7% |
| 资本支出强度资本支出/营收 | 2.1% | 71.9% |
| 现金转化率经营现金流/净利润 | 1.72× | 5.06× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $-2.5B |
8季度趋势，按日历期对齐
经营现金流BDXETR
| Q4 25 | $657.0M | $1.2B | ||
| Q3 25 | $1.4B | $2.1B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $164.0M | $536.2M | ||
| Q4 24 | $693.0M | $1.4B | ||
| Q3 24 | $1.2B | $1.6B | ||
| Q2 24 | $1.3B | $1.0B | ||
| Q1 24 | $514.0M | $521.1M |
自由现金流BDXETR
| Q4 25 | $549.0M | $-909.7M | ||
| Q3 25 | $1.0B | $246.0M | ||
| Q2 25 | $1.0B | $-746.6M | ||
| Q1 25 | $35.0M | $-1.1B | ||
| Q4 24 | $588.0M | $-193.8M | ||
| Q3 24 | $882.0M | $421.8M | ||
| Q2 24 | $1.1B | $-137.8M | ||
| Q1 24 | $380.0M | $-440.1M |
自由现金流率BDXETR
| Q4 25 | 10.5% | -30.7% | ||
| Q3 25 | 17.0% | 6.5% | ||
| Q2 25 | 19.0% | -22.4% | ||
| Q1 25 | 0.7% | -39.5% | ||
| Q4 24 | 11.4% | -7.1% | ||
| Q3 24 | 16.2% | 12.4% | ||
| Q2 24 | 22.4% | -4.7% | ||
| Q1 24 | 7.5% | -15.7% |
资本支出强度BDXETR
| Q4 25 | 2.1% | 71.9% | ||
| Q3 25 | 6.0% | 49.5% | ||
| Q2 25 | 3.2% | 60.3% | ||
| Q1 25 | 2.4% | 58.3% | ||
| Q4 24 | 2.0% | 57.4% | ||
| Q3 24 | 5.4% | 33.7% | ||
| Q2 24 | 3.6% | 39.4% | ||
| Q1 24 | 2.7% | 34.4% |
现金转化率BDXETR
| Q4 25 | 1.72× | 5.06× | ||
| Q3 25 | 2.75× | 3.06× | ||
| Q2 25 | 2.12× | 2.67× | ||
| Q1 25 | 0.53× | 1.48× | ||
| Q4 24 | 2.29× | 4.80× | ||
| Q3 24 | 2.94× | 2.42× | ||
| Q2 24 | 2.66× | 19.82× | ||
| Q1 24 | 0.96× | 6.81× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
ETR
| Electricity Us Regulated | $2.9B | 100% |
| Other | $13.7M | 0% |
